NICE-recommended tumour profiling tests could prevent breast cancer chemotherapy

NICE’s independent diagnostic advisory committee reviewed the evidence behind tumour profiling tests which are designed to provide information on the genetic makeup of breast cancer tumours. This information can be used to guide the treatment of women who have been through the menopause, and men, with oestrogen receptor (ER) or progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-negative…